In addition, decreased expression of Lhx6 has been reported in diabetes, tumors, and inflammatory environments, and Lhx6 is also involved in signaling pathways that regulate disease progression and regression, including p38, NF-κB and Wnt/β-catenin (Chen et al. 2019; Hwang et al. 2024). Here, NFKB1 is linked to diabetes mellitus.